Tenet Healthcare’s first quarter results were met with a negative market reaction, as investors weighed flat same-store sales and cautious commentary on payer mix and exchange enrollment against notable margin expansion. Management pointed to disciplined expense management, operational efficiencies, and robust performance in the ambulatory surgery division as key contributors. CEO Saum Sutaria acknowledged challenges from winter storms and cyberattack disruptions, but highlighted that expense initiatives and automation “more than offset the expected and unexpected headwinds that arose in the quarter.”
Is now the time to buy THC? Find out in our full research report (it’s free for active Edge members).
Tenet Healthcare (THC) Q1 CY2026 Highlights:
- Revenue: $5.37 billion vs analyst estimates of $5.39 billion (2.8% year-on-year growth, in line)
- Adjusted EPS: $4.82 vs analyst estimates of $4.17 (15.7% beat)
- Adjusted EBITDA: $1.16 billion vs analyst estimates of $1.12 billion (21.6% margin, 3.7% beat)
- The company reconfirmed its revenue guidance for the full year of $21.9 billion at the midpoint
- Management raised its full-year Adjusted EPS guidance to $17.53 at the midpoint, a 1.2% increase
- EBITDA guidance for the full year is $4.64 billion at the midpoint, in line with analyst expectations
- Operating Margin: 24.1%, up from 18.1% in the same quarter last year
- Same-Store Sales were flat year on year (2.9% in the same quarter last year)
- Market Capitalization: $16.75 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Tenet Healthcare’s Q1 Earnings Call
- Ryan Langston (TD Cowen) asked about rising payer denials and uncompensated care trends; CEO Saum Sutaria said denials remain high but flat versus prior quarters, and a slight increase in uncompensated care is likely linked to exchange subsidy expiration.
- Albert Rice (UBS) questioned which hospital markets showed the most improvement; Sutaria said margin gains were widespread, driven by high-acuity service growth and local execution, with all markets adopting efficiency initiatives.
- Jason Cassorla (Guggenheim Partners) inquired about length of stay improvements; Sutaria explained that reductions were achieved despite higher patient complexity, crediting automation and capacity management tools for freeing up hospital beds and avoiding unnecessary capital spend.
- Brian Tanquilut (Jefferies) asked about Medicaid trends; Sutaria observed slight Medicaid declines, especially in California, attributing this to disenrollment or renewal issues, but said the impact on hospital operations was minimal due to ongoing care for critical cases.
- Craig Hettenbach (Morgan Stanley) sought details on USPI’s M&A strategy; Sutaria cited a strong track record in integrating ambulatory centers, clinical quality improvements, and ongoing selectivity in acquisitions as reasons USPI is a preferred partner in the sector.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will watch (1) the pace of ambulatory network expansion and its contribution to EBITDA, (2) margin resilience in the hospital segment as exchange and Medicaid coverage trends evolve, and (3) the impact of technology and automation on expense ratios and productivity. Developments in outpatient reimbursement policy and regulatory shifts will also be closely monitored for their potential to alter the payer mix and revenue outlook.
Tenet Healthcare currently trades at $194.51, up from $180.10 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
